Posted by Michael Wonder on 26 Nov 2019
Zejula is included in the high-cost protection with limitation
25 November 2019 - Zejula (niraparib) is included in the high-cost, limited-subsidy protection from December 1, 2019.
The limitation applies to the maintenance treatment of adult patients with platinum-sensitive recurrence of high-grade serous ovarian, tubular or primary peritoneal cancer and who responded in full or in part to platinum-based chemotherapy.
TLV has had tripartite consultations with the company and county councils (the regions). Within the framework of these consultations, the company and county councils (the regions) have signed a side agreement for Zejula, which will reduce the processing costs for Zejula. This side agreement is part of TLV's decision basis.
